(See the Editorial Commentary by Oxman and Schmader on pages 920-2.)
Herpes zoster (HZ) is a painful and often debilitating disease caused by reactivation of varicella zoster virus (VZV) that remains dormant after primary infection. 30 HZ incidence increases substantially in adults as they age, but the other key risk factor for HZ is immunosuppression, whether due to human immunodeficiency virus (HIV) infection [1] , treatment of autoimmune diseases [2] [3] [4] , stem cell or solid organ transplant [5] [6] [7] , hemato-35 logic malignancies, or chemotherapeutic treatment of solid tumors [8, 9] . Rates of HZ in patients undergoing chemotherapy for solid tumors, for instance, are almost 4 times the rate in healthy adults [8, 9] . In addition, immunosuppressed individuals are at greatest risk of the 40 most severe ophthalmologic and neurologic complications of HZ, including visceral dissemination [10] . Zoster vaccine (Zostavax) has been shown to be safe and protective in immunocompetent elderly populations [11] [12] [13] , but the vaccine is comprised of the live 45 attenuated Oka strain of VZV and is thus contraindicated in immunocompromised persons due to a lack of data on vaccine safety and efficacy in these patients; the Shingles Prevention Study excluded patients who were immunosuppressed due to malignancy, HIV infection, 50 immunosuppressive or cytotoxic chemotherapy, or high-dose corticosteroid therapy. These patients were thought, on a theoretical basis, to be at higher risk for side effects and less likely to benefit from the vaccine [13] . Most persons with immunocompromising conditions 55 acquire the conditions as adults. Therefore, there are opportunities to vaccinate these persons before they become immunocompromised. In one approach, by widely offering zoster vaccine to the recommended population of adults aged ≥60 years, a portion of the vaccinated adults will discover months 60 or years later that they acquired a medical condition that is immunocompromising or that requires immunocompromising treatments. Alternatively, adults aged ≥60 years who remain unvaccinated may discover that they acquired a medical condition that requires immunocompromising treatments in coming 65 weeks or months; the Advisory Committee on Immunization Practices (ACIP) recommends that these persons be offered zoster vaccine while their immunity is intact if it can be administered at least 14 days, and ideally 1 month, before initiation of immunosuppressive therapy [14] . 70 However, the safety and effectiveness of these approaches have never been empirically tested in a study. It is plausible that VZV-specific immunity will be lost as more general immunosuppression occurs. In fact, live attenuated zoster vaccine can establish latency and itself reactivate to cause zoster [15] . This is 75 rare in immunocompetent individuals, but it is possible that the vaccine virus might contribute to the risk of zoster and its complications once immunosuppression occurs.
As the expected number of elderly persons who will become immunocompromised due to treatments or diseases increases, 80 it is important to evaluate the safety and effectiveness of zoster vaccination in patients who subsequently receive immunosuppressive treatments. In this study, we identified a cohort of individuals who received myelosuppressive chemotherapy at age 60 years and older and compared the incidence of HZ after che-85 motherapy between those who had been vaccinated with zoster vaccine before chemotherapy and those who had not.
METHODS

Setting
The study was conducted among members of Kaiser Permanente 90 Southern California (KPSC), an integrated healthcare system that provides comprehensive prepaid health services for its 3.6 million members. Members are racially diverse and include the entire sociodemographic spectrum, and >99% are community-dwelling. The demographic makeup of the KPSC membership closely mir-95 rors the Southern California population [16] 
Exposure
The exposure variable was receipt of zoster vaccine after 1 January 2007 and prior to the initiation of chemotherapy. Subjects who received zoster vaccine after initiation of chemotherapy were not included. 135 
Follow-up Period
The period of follow-up started from the date of chemotherapy and ended at 30 months of follow-up or the date of HZ occurrence, termination of KPSC membership, or 31 December 2012, whichever was earliest.
140
Incidence of HZ
Incidence of HZ during the follow-up period was identified electronically by the first occurrence of an International Classification of Diseases, Ninth Revision (ICD-9) diagnosis code of 053.xx assigned in the inpatient, outpatient, and emergency de-145 partment settings. Medical records for patients identified from inpatient settings were reviewed to determine if the hospitalization was due to HZ. If HZ developed during a hospital stay for another condition, it was considered as an incident HZ but not HZ requiring hospitalization. 150 
Covariates
Cohort members were categorized to assess factors associated with vaccination and risk of HZ, including age, sex, race, healthcare utilization, and use of antiviral medications (acyclovir, famciclovir, or valacyclovir) during the follow-up period. 155 Healthcare utilization was defined as the number of hospitalizations or outpatient or emergency department visits in the 6 months prior to the follow-up period.
Statistical Analysis
The distribution of baseline characteristics was compared be-160 tween the vaccinated and unvaccinated populations, including age, sex, race, healthcare utilization prior to chemotherapy, and use of antiviral medications during follow-up. The time from vaccination to chemotherapy was also calculated for the vaccinated group. The 30-month cumulative incidence of HZ after chemo-165 therapy was estimated by Kaplan-Meier method, and the difference between the vaccinated and the unvaccinated population was tested by the log-rank test. Incidence rate of HZ was estimated by dividing the number of HZ cases by the total number of person-years of follow-up. The 95% confidence intervals (CIs) 170 were estimated assuming that occurrence of HZ follows a Poisson distribution. Hazard ratios (HRs) and 95% CIs of HZ comparing the vaccinated and the unvaccinated cohort were estimated using Cox proportional hazards regression models with chemotherapy (on, off) treated as a time-dependent variable, and with adjust-175 ment for potential confounding factors, including age (years); sex (male, female); race (white, black, Asian/Pacific Islander, Hispanic, other/multiple/unknown); number of outpatient visits (0, 1-4, 5-10, ≥11), emergency department visits (0, 1, ≥2), and hospitalizations (0, 1, ≥2) in the 6 months prior to chemothera-180 py; and use of antiviral medications during follow-up time (yes, no). Time on chemotherapy was calculated from the initiation of treatment to 30 days after the end of a cycle [17] . Use of antiviral medications was included in the models because patients might receive them to treat other viral infections (ie, herpes simplex) or 185 for prophylaxis [18] . Hazard ratios were also presented for age, sex, and race categories. Our sample size was sufficient to detect a relative risk of HZ incidence between the vaccinated and unvaccinated cohorts as low as 0.75 during the study interval, with power of >80% and type I error rate of 0.05. We set the signifi-190 cance at 0.05 based on a 2-sided test. We used SAS Enterprise Guide 4.2 (SAS Institute, Cary, North Carolina) for all analyses.
RESULTS
There were 4710 vaccinated members and 16 766 unvaccinated members included in the study. Among the vaccinated cohort, 195 74 (1.6%), 78 (1.6%), 326 (6.9%), 584 (12.4%), and 3648 (77.5%) members were vaccinated in ≤30 days, 31-59 days, 60-180 days, 181-365 days, and >365 days, respectively, before initiation of chemotherapy. The baseline characteristics of the study cohorts by vaccination status are summarized in Table 1 .
200
Age and sex distributions were similar between cohorts. There were fewer black and Hispanic persons in the vaccinated cohort. In the 6 months prior to initiation of chemotherapy, the unvaccinated cohort had a higher proportion of subjects with emergency department visits or hospitalizations, but there were no 205 differences in terms of the more frequent outpatient visits.
The incidence rate of HZ in the vaccinated and the unvaccinated cohort is presented in Table 2 . Overall, there were 91 and 583 HZ incident cases in the vaccinated and the unvaccinated cohort, respectively. The incidence rate was 12.87 (95% CI, The adjusted rate ratio for HZ between the vaccinated and the unvaccinated cohorts was 0.58 (95% CI, .46-.73) and showed no 230 substantial variation across age, sex, or race group (Table 3) .
DISCUSSION
Our study demonstrates the effectiveness of zoster vaccine in a cohort of adults aged ≥60 years who subsequently received chemotherapy. The protection was robust by age, sex, and race 235 group; in fact, it was similar to the vaccine protection reported in a comparable but immunocompetent cohort (adjusted HR, 0.58 [95% CI, .46-.73] vs 0.45 [95% CI, .42-.48], respectively) [12] . This comparable performance is surprising because effectiveness in the immunocompetent population was assessed im-240 mediately after vaccination, whereas effectiveness in this study was assessed following initiation of chemotherapy, a mean of 2.36 years after vaccination, after more time had elapsed for potential waning of protection. We believe that our results are not likely due to confounding, because the decision by the patients 245 and their physicians regarding zoster vaccination was made almost randomly, many months to years before cancer was diagnosed. For this same reason, we do not believe that our cohorts differed in terms of the degree of immunosuppression they ultimately experienced.
250
The 42% protection that we found in our study translates to a large reduction in disease burden given the high incidence of HZ in this high-risk population. The HZ incidence rates that we found in unvaccinated patients receiving chemotherapy were 22.05 per 1000 person-years (95% CI, 20.33-23.92), much higher 255 than the rates in comparable immunocompetent patients (13.0 [95% CI, 12.6-13.3]) [12] . Habel et al [8] reported very similar rates in patients receiving chemotherapy (23.0 [95% CI, 18.9-27.1]). In fact, by preventing HZ-associated hospitalizations, the vaccine also appeared to prevent the severe disease manifestations 260 that often occur in the immunocompromised population. Our study has potentially important policy implications, as the live attenuated zoster vaccine is currently contraindicated in immunocompromised patients, the population at highest risk of HZ and its severe complications. Although observational studies 265 provide evidence that Zostavax may be effective and safe in these patients [11, 19] , additional studies are needed to provide reassurance that this practice would be safe. Our data suggest that VZV-specific immunity is well maintained in the presence of chemotherapy-induced immunosuppression. Physicians 270 can therefore be assured that patients will retain significant protection following vaccination even if they must subsequently undergo chemotherapy. With a lifetime cancer risk of close to 40% among 60-year-old adults [20] , our results provide an additional rationale for offering HZ vaccination to patients in 275 a timely manner, adding to the benefit of the vaccine [21] . The ACIP currently recommends that zoster vaccine be specifically offered to patients at least 14-30 days before they undergo immunocompromising treatments in order to obtain the benefits of vaccine protection without the risks of dissemi-280 nation of this live attenuated vaccine [14] . However, this recommendation has never been formally evaluated for safety and efficacy. Notably, in our study, only 152 patients (3.2%) started chemotherapy within 60 days after vaccination, fewer patients than were vaccinated during other windows of time.
285
More importantly, in contrast to HZ rates that were considerably lower in most vaccine recipients, who subsequently underwent chemotherapy compared with nonrecipients, this pattern was not seen for those patients who received chemotherapy within 60 days after vaccination. Given the small number of patients 290 in this group, the lack of an observed reduction in HZ risk may be a random, artifactual finding. Alternatively, it may be a real phenomenon; perhaps immunogenicity is unable to fully develop when chemotherapy is administered within weeks following vaccination. We believe, however, that the higher HZ rates seen in 295 this group reflect residual confounding: For patients anticipating chemotherapy, the nature of the cancer and the treatment regimen would likely play a key role in the decision to vaccinate, leading to confounding by indication. This bias is not plausible among patients who develop cancer months or years in the fu-300 ture. Our findings suggest that zoster vaccination continues to benefit patients who develop cancer and require chemotherapy ≥60 days in the future. In addition to the potential bias noted above, there are other limitations to our study. First, electronic health data can only capture information on medically attended 305 HZ. In a population-based survey, 95% of 141 patients aged ≥60 years who experienced HZ sought medical attention [22] . Our immunocompromised patients had ready access to healthcare in the KPSC system and were frequent healthcare utilizers; they would have been even more likely to seek care for their HZ epi-310 sodes. However, it is possible that there were some differences in HZ ascertainment as a function of vaccination status. The vaccine recipients may have also differed in their underlying risk of HZ. We controlled for the use of anti-VZV prophylaxis in our analysis, but occasional patients may have received other anti-VZV 315 medications and this may have varied by vaccination status.
Given the size of the study population, we were also unable to validate the ICD-9-based HZ diagnoses in the cohorts. Prior studies have shown that the 85%-100% of ICD-9-based HZ proved to be HZ upon record review [23, 24] . Furthermore, we 320 have shown elsewhere that physician-diagnosed HZ at KPSC was correctly diagnosed regardless of HZ vaccination status, based on polymerase chain reaction confirmation of specimens taken from the patients' skin lesions [25] . We were also not able to explore potential HZ risk factors and outcomes using 325 record reviews. As a result, we were unable to assess rates of postherpetic neuralgia or rates of potential adverse safety events. Finally, although we were able to identify patients being hospitalized for HZ, we were not able to assess the severity of their disease. We only assessed the impact of vaccination on HZ rates fol-330 lowing chemotherapy; although the results are reassuring, we cannot assume that they would hold for other types of iatrogenic immunosuppression. The effectiveness of zoster vaccine in patients undergoing various types of immunosuppression will become increasingly important as the number of indications 335 for immunosuppression increases.
In conclusion, in our study, persons treated with chemotherapy who are at high risk of HZ and its sequelae received substantial protection through zoster vaccination. As high proportion of adults develop cancer during their lifetime and 340 require chemotherapy, our findings provide an additional rationale for offering zoster vaccine to adults for whom it is indicated, before the vaccine becomes contraindicated.
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